Metraipolis › archive › dc_8fa9c28ac3ca

Early GLP-1 Agonist Use and Cancer Risk in Type 2 Diabetes: A Real-World Data Cohort Study — Europe PMC PMID:41502515

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41502515
DOI
10.32604/or.2025.072875
License (as archived)
solo-consultazione
Archived
2026-11-07T08:11:39.013Z
SHA-256 of the archived text
e201e14c7e9781a642018762a0ecf1575d63cfbc3caf44fe261add66a6df8e59
Stable URL of this page
https://metraipolis.com/documento/dc_8fa9c28ac3ca

How to cite

Early GLP-1 Agonist Use and Cancer Risk in Type 2 Diabetes: A Real-World Data Cohort Study — Europe PMC PMID:41502515 — Europe PMC (en), https://europepmc.org/article/MED/41502515 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_8fa9c28ac3ca (Metraipolis archive dc_8fa9c28ac3ca, sha256 e201e14c7e9781a642018762a0ecf1575d63cfbc3caf44fe261add66a6df8e59)
BibTeX
@misc{dc8fa9c28ac3ca,
  title = {Early GLP-1 Agonist Use and Cancer Risk in Type 2 Diabetes: A Real-World Data Cohort Study — Europe PMC PMID:41502515},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41502515},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_8fa9c28ac3ca; sha256 e201e14c7e9781a642018762a0ecf1575d63cfbc3caf44fe261add66a6df8e59},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41502515. Agents can read the archived copy with the MCP tool read_document.